Lung Cancer
Aug 16, 2021
To evaluate the quality of robust stereotactic body proton therapy (RSBPT) plans generated by one-clicking scripting method for patients with lung cancer.Retrospective analysis was performed on fifty ...
Aug 05, 2021
A stable and accurate automatic tumor delineation method has been developed to facilitate the intelligent design of lung cancer radiotherapy process. The purpose of this paper is to introduce an autom...
Jul 29, 2021
Patients with Eastern Cooperative Oncology Group Performance Status 2 (ECOG PS 2) are not included in most randomized clinical trials and registry studies. Nevertheless, immune checkpoint inhibitors a...
Jul 22, 2021
Sublobar resection is suitable for peripheral cT1N0M0 non-small-cell lung cancer (NSCLC). The traditional PET-CT criterion (lymph node size ≥1.0 cm or SUVmax ≥2.5) for predicting lymph nodes metas...
Jul 12, 2021
Oxoplatin-B, a platinum(IV) complex [Pt(NH)Cl(L)(OH)] (1) of 4-methylbenzoic acid (HL) functionalized with 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) was prepared, characterized and its antit...
Jun 24, 2021
Thoracic radiotherapy is complicated by acute radiation-induced adverse events such as radiation pneumonitis (RP) and radiation esophagitis (RE). Based on preclinical work and a randomized pilot tria...
Jun 03, 2021
Torque teno virus (TTV) is a ubiquitous non-pathogenic virus, which is suppressed in immunological healthy individuals but replicates in immune compromised patients. Thus, TTV load is a suitable bioma...
Mar 08, 2021
Immune escape and low response to immunotherapy are crucial challenges in present lung cancer treatment. In this study, we constructed a new immune-related classifier based on CXCL13/CXCR5, an importa...
Feb 15, 2021
This study aimed to investigate the trend of cardiovascular disease (CVD)-specific mortality in patients with non-small cell lung cancer (NSCLC) and identify prognostic factors for CVD-specific death ...
Feb 15, 2021
Patients with a prior history of cancer (PHC) are at increased risk of second primary malignancy, of which lung cancer is the most common. We compared the performance metrics of positive screening rat...
Feb 15, 2021
This study aimed to evaluate the impact of KRAS status on the efficacy of first-line immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer (NSCLC).Patients with advan...
Dec 31, 2020
Molecules involved in crosstalk between tumor cells and fibroblasts play vital roles in tumor progression. Extracellular matrix proteins, whose abundance is altered after being affected by tumor-deriv...
Dec 31, 2020
Tumor necrosis factor (TNF) and its receptors are widely expressed in non-small cell lung cancer (NSCLC). TNF has an established role in inflammation and also plays a key role in inflammation-induced ...
Sep 18, 2020
Approximately 5% of all non-small-cell lung cancers (NSCLC) are anaplastic lymphoma kinase-positive (ALK-positive). This study aims to compare the safety and efficacy of alectinib with crizotinib as t...
Sep 18, 2020
Malignant pleural mesothelioma (MPM) is a cancer of the lining of the lungs, characterized by chest pain, shortness of breath, and dry cough. Nintedanib is a medication that targets various receptors ...
Sep 18, 2020
Non-small-cell lung carcinoma (NSCLC) is one of the most common types of lung cancers. The use of tyrosine kinase inhibitors (TKIs) is impeded by the emergence of the Thr790Met mutation in a majority ...
Sep 01, 2020
This course discusses the key findings of five studies presented at the 2020 virtual Annual Meeting of the American Association for Thoracic Surgery....
Aug 18, 2020
Angiotensin-converting enzyme (ACE) inhibitors help lower your blood pressure by relaxing your veins and arteries. Recent evidence suggests that the use of ACE inhibitors may increase the risk of lung...
Jun 12, 2020
Risk increases as more cigarettes are smoked According to the Office of Minority Health of the Health and Human Services Administration, African Americans are 50% more likely to have a stroke than th...
Jun 02, 2020
Overall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzumab deruxte...